Name	Marta Chesi
Current Position & Affiliation	Associate Professor of Medicine, Mayo Clinic Arizona
Country	USA
Major Field	Molecular Pathogenesis of Multiple Myeloma

Educational Background

1985 - BA in Humanities from Liceo Tito Livio, Milan, Italy
1993 - PhD in Biochemistry from State University of Milan, Italy

Professional Experience

1994-1997 Post doctoral fellowship at National Cancer Institute, Bethesda, MD, USA
1998-1999 Research Associate - Weill Cornell Medical College, New York, NY, USA
1999-2001 Instructor in Medicine - Weill Cornell Medical College, New York, NY, USA
2002-2004 Assistant Professor of Biochemistry - Weill Cornell Medical College, New York, NY,
2005-2015 Professional Associate in Research, Mayo Clinic Scottsdale, USA
2016 Associate Professor of Medicine, Mayo Clinic Scottsdale, USA.

Other Experience and Professional Memberships

2010 – Present, International Myeloma Society, Member
2012 – Present, International Myeloma Foundation, Member
2013 – Present, American Association for Cancer Research, Member
2014 – Present, American Society of Hematology, Member
2023 – Present, Scientific Advisor for Barrie Dalgleish Center for Myeloma and Related Cancer
2024 – Present, Blood Editorial Member
2024 – Present, Blood Neoplasia Editorial Member
2026 - American Society of Hematology, Member, Scientific Committee on Plasma Cell neoplasia

Main Scientific Publications

- **Chesi M**, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997.
- **Chesi M**, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, Schrock E, Ried T, Kuehl WM. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood. 1998.
- **Chesi M**, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998.
- **Chesi M**, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA, Kuehl WM, Bergsagel PL. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood. 2001.

- Keats JJ, Fonseca R, **Chesi M**, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007.
- **Chesi M**, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, Valdez R, Palmer SE, Haas SS, Stewart AK, Fonseca R, Kremer R, Cattoretti G, Bergsagel PL. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008.
- Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, **Chesi M**, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011.
- **Chesi M**, Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M, Stewart AK, Johnstone RW, Bergsagel PL. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood. 2012.
- Keats JJ, **Chesi M**, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012.
- **Chesi M**, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, Calcinotto A, Riggs DL, Keane N, Ahmann GJ, Morrison KM, Fonseca R, Lacy MQ, Dingli D, Kumar SK, Ailawadhi S, Dispenzieri A, Buadi F, Gertz MA, Reeder CB, Lin Y, Chanan-Khan AA, Stewart AK, Fooksman D, Bergsagel PL. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med. 2016.
- Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, Shi CX, Stein CK, Bergsagel M, Chau B,Wheeler ML, Bezman N, Wang F, Strop P, Bergsagel PL, **Chesi M**. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021.
- Welsh SJ, Barwick BG, Meermeier EW, Riggs DL, Shi CX, Zhu YX, Sharik ME, Du MT, Abrego Rocha LD, Garbitt VM, Stein CK, Petit JL, Meurice N, Tafoya Alvarado Y, Fonseca R, Todd KT, Brown S, Hammond ZJ, Cuc NH, Wittenberg C, Herzog C, Roschke AV, Demchenko YN, Chen WD, Li P, Liao W, Leonard WJ, Lonial S, Bahlis NJ, Neri P, Boise LH, **Chesi M**, Bergsagel PL. Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma. Blood Cancer Discov. 2024.
- Maura F, Coffey DG, Stein CK, Braggio E, Ziccheddu B, Sharik ME, Du MT, Tafoya Alvarado Y, Shi CX, Zhu YX, Meermeier EW, Morgan GJ, Landgren O, Bergsagel PL, **Chesi M**. The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans. Nat Commun. 2024.
- Meermeier EW, Pfeffer K, Stein CK, Sharik M, Du MT, Tafoya Alvarado Y, Shi CX, Zhu YX, Bergsagel PL, **Chesi M**. An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden. Blood. 2025.